Skip to Content

New Leafreport Research Reveals More Than Half of Tested CBD Teas and Coffees Had Inaccurate CBD Levels

Report Finds That Only 48% of Tested Products Had CBD Levels Within 10% Of The Label

TEL AVIV, Israel, Sept. 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- (“Leafreport” or the “Company”), the CBD industry's peer-reviewed watchdog website, announced today the results from a comprehensive review of cannabidiol (CBD) products from a variety of brands aimed at verifying if the label claims being made about potency were correct. Among the research findings, it was found that a little over half (52%) of the 29 products sent for testing contained the wrong amount of CBD. They were off from the labeled CBD content by anywhere from 11.5% to 62%.

Leafreport utilized a third-party testing facility for the report. Among the findings, the Company found that out of 14 teas and coffees that were advertised to contain broad or full-spectrum hemp extract, 11 (79%) were accurate and only 3 contained CBD. In addition, 14 (48%) of the tested products had CBD levels within 10% of the label, which is required for an A rating.

The testing also found that brands with multiple products scored well for one product but had lower scores for another product, suggesting problems with consistency.

“You can find CBD in almost anything, including tea and coffee, but do these products contain as much CBD as advertised, and are they accurately delivering what is promised to consumers? We felt it was important to test these products to get an answer to these questions,” said Lital Shafir, the head of product at Leafreport. “Leafreport’s mission is to help promote transparency across the CBD industry and educate consumers so they can access products that are safe and offer the contents being advertised. Reports like this shed light on CBD products, educate consumers and hopefully encourage companies to be more diligent about their testing standards.”

In addition, Leafreport tested three hemp-containing teas and coffees that didn’t claim to provide a specific amount of CBD. The tests found CBD and other cannabinoids in all three.

Leafreport utilized SC Labs, a reputable cannabis testing lab. The lab technicians tested the products and recorded the results in documents called certificates of analysis (CoAs). Next, Leafreport compared the level of CBD shown on the CoAs to the advertised amount and also looked at what other cannabinoids were detected by the tests, especially if the manufacturer claimed to use broad-spectrum or full-spectrum hemp extract.

This report is one of many completed by Leafreport aimed at informing consumers about various aspects of the CBD industry. The Company has previously sent CBD products to the cannabis testing lab Canalysis to see if they contained the advertised levels of CBD, among other tests. These reports include recent deep-dives into topicalsediblesbeverages, and more.

To read the full report from Leafreport, visit:

Visit for additional reports and product information for consumers related to CBD products and other topics. 

About Leafreport: Leafreport is a science-based, peer-reviewed website designed to help consumers navigate the landscape of CBD. The company's mission is to introduce transparency into the CBD industry through its patient-focused, educational content and medical reviews. The company medical review team consists of physicians, chemists, nutritionists, pharmacists, chemists and naturopaths.


Lital Shafir

Head of product

Kyle Porter

CMW Media

(858) 264-6600

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.